Antidiabetic drugs and stroke risk. Current evidence

Published: 20 September 2017
Author(s): Luis Castilla-Guerra, María del Carmen Fernandez-Moreno, David Leon-Jimenez, Eduardo Carmona-Nimo
Section: Narrative Review

Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be responsible for >8% of first ischemic strokes. Therefore, the way to prevent stroke in these patients has become an important issue.Traditionally, glucose-lowering drugs had not been shown to protect against stroke. Moreover, several antidiabetic drugs (i.e., sulfonylureas, rosiglitazone) have been reported to be associated with increased risks of CVD and stroke.